2 Steps Forward, 1 Step Back

One step back but 2 steps forward.

There have been major advances reported over the past decade in previously untreated chronic lymphocytic leukemia (CLL) with chemo-immunotherapy approaches now the treatment of choice.2 A decade ago, chlorambucil was the treatment of choice. However, CLL is a disease of the elderly with a median age at diagnosis of 72 years, and almost 70% of CLL patients are older than 65 years at the time of ...

Two steps forward, one step back.

Participants at a community health information network in Glens Falls, N.Y., have come face-to-face with obstacles that could have meant the end to this rural health network that the New York Department of Health and the John A. Hartford Foundation helped launch more than two years ago. Instead, John Laliberte, Glens Falls Hospital's director of information systems, and the rest of the IS team ...

One step forward, two steps back.

Prior research on child poverty has focused heavily on the roles of family structure and, to a lesser extent, parental work patterns to explain trends over time and differences across groups. However, immigrant child poverty has increased significantly over the past three decades even though labor force participation is high among immigrants and immigrant families are likely to be headed by a m...

One step forward and two steps back.

Mesenchymal stem cell therapy: Two steps forward, one step back.

Mesenchymal stem cell (MSC) therapy is poised to establish a new clinical paradigm; however, recent trials have produced mixed results. Although MSC were originally considered to treat connective tissue defects, preclinical studies revealed potent immunomodulatory properties that prompted the use of MSC to treat numerous inflammatory conditions. Unfortunately, although clinical trials have met ...